TABLE 5.
Risk factors associated with 28-d COVID-19-associated lethality among the 232 subjects with confirmed severe acute respiratory syndrome coronavirus 2 infection after the first vaccine dose
| Factors | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| P | OR (95% CI) | P | OR (95% CI) | |
| Age (each additional y of age), y | 0.002 | 1.05 (1.02-1.09) | 0.004 | 1.05 (1.02-1.09) |
| Male gender (vs female gender) | 0.521 | 1.21 (0.68-2.17) | – | |
| Diabetes (vs no diabetes) | 0.027 | 2.63 (1.11-6.20) | 0.268 | 1.70 (0.66-4.35) |
| Recipient from deceased donor (vs living donor) | 0.041 | 1.96 (1.03-3.75) | 0.081 | 1.86 (0.93-3.72) |
| Length of transplant, y | 0.591 | 0.99 (0.95-1.03) | – | |
| Maintenance regimen | ||||
| TAC-Pred-AZA | Ref | – | ||
| TAC-Pred-MPA | 0.642 | 0.85 (0.43-1.67) | ||
| CSA-Pred-AZA | 0.111 | 0.46 (0.17-1.20) | ||
| TAC-Pred-mTORi | 0.765 | 0.86 (0.31-2.37) | ||
| Others | 0.892 | 1.09 (0.33-3.62) | ||
| COVID-19 after the first dose | Ref | |||
| COVID-19 <15 d after the second dose | 0.379 | 0.67 (0.27-1.64) | 0.223 | 0.55 (0.21-1.44) |
| COVID-19 ≥15 d after the second dose | 0.001 | 0.35 (0.18-0.65) | 0.001 | 0.32 (0.16-0.63) |
AZA, azathioprine; CI, confidence interval; COVID-19, coronavirus disease 2019; CSA, cyclosporine; MPA, mycophenolic acid; mTORi, mechanistic target of rapamycin inhibitor; OR, odds ratio; Pred, prednisone; ref, reference; TAC, tacrolimus.